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Purpose: The purpose of this study was to evaluate the incidence of thrombotic 
complications in patients with deep vein thrombosis (DVT) who were treated with 
percutaneous inferior vena caval interruption in place of anticoagulation. 
Methods: A retrospective r view of all percutaneously placed inferior vena cava filters for 
1 year, August 1993 through July 1994, was performed. 
Results: Thirty-three percutaneous inferior vena cava filters were placed in 32 patients. The 
underlying disease was pulmonary embolism in 15 (47%) and DVT in 17 (53%) patients. 
Of patients with pulmonary embolism, 11 had a documented DVT, and four were not 
evaluated for DVT. There were 14 men and 18 women, with a mean age of 63.5 years 
(range 24 to 93 years). Indications for vena caval interruption were recurrent pulmonary 
embolism with therapeutic anticoagulation ( = 2 [6%]), prophylactic insertion with 
documented pulmonary embolism and therapeutic anticoagulation (n = 8 [25%]), 
documented pulmonary embolism and absolute contraindication to anticoagulation 
(n = 5 [16%]), documented DVT and absolute contraindication to anticoagulation 
(n = 2 [6%]), prophylactic nsertion with documented DVT and therapeutic anticoagu- 
lation (n --- 5 [16%]), and documented DVT with relative contraindication to anticoagu- 
lation (n - 10 [31%]). Of the 32 patients with inferior vena cava filters, 17 were not given 
anticoagulants (7 absolute contraindications, 10relative contraindications), and 15 were 
given anticoagulants. Insertion of a percutaneous inferior vena cava filter in patients who 
were not given anticoagulants was followed by the development of phlegmasia cerulea 
dolens in four patients (24%), which was bilateral in two patients; one patient eventually 
died. No patients treated with inferior vena cava filter and anticoagulation had 
development of phlegmasia. 
Conclusions: Percutaneous inferior vena caval interruption effectively prevents pulmonary 
embolism in patients with DVT but does not impact he underlying thrombotic process 
and in fact may contribute to progressive thrombosis in patients who are not given 
anticoagulants. Anticoagulation with intravenous heparin is safe and effective therapy for 
DVT in most patients. We believe that percutaneous insertion ofvena cava filters should 
not replace anticoagulation i  routine proximal DVT, and those patients who require an 
inferior vena cava filter for failure of anticoagulation should continue to receive heparin 
to treat the primary thrombotic process. We caution that relative contraindications to
anticoagulation should be carefully scrutinized before recommending vena cava interrup- 
tion as a primary therapy for DVT. (J VASC SURG 1995;22:606-11.) 
From the Division of Vascular Surgery Stanford University School 
of Medicine, Stanford. 
Presented at the Seventh Annual Meeting, American Venous 
Forum, Feb. 23-25, 1995, Fort Lauderdale, Fla. 
Reprint requests: E. John Harris, Jr., MD, Division of Vascular 
Surgery, 300 Pasteur Dr., Suite H3630, Stanford, CA 94305- 
5450. 
Copyright © 1995 by The Society for Vascular Surgery and 
International Society for Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/95/$3.00 + 24/6/66789 
606 
Deep venous thrombosis (DVT) may be associ- 
ated with two potentially serious acute compli- 
cations: phlegmasia cerulea dolens and pulmonary 
embolism. Anticoagulation is the preferred treatment 
for DVT because it arrests the thrombotic process, 
allowing natural thrombolysis to occur, and is 
effective in preventing the development of phlegma- 
sia cerulea dolens and pulmonary embolism. 14 Re- 
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cent advances in percutaneous delivery systems have 
increased the use of vena caval interruption in 
thromboembolic disorders, 7 Placement ofvena cava 
filters in patients with documented pulmonary em- 
bolism or free-floating iliofemoral thrombus has been 
proven efficacious, but most of these patients con- 
tinue to receive anticoagulants after inferior vena cava 
(1VC) filter placement. 8 Some advocate IVC filtra- 
tion as the primary means of therapy in venous 
thromboembolic disease, without anticoagulation, 
but the effectiveness of this mode of therapy is 
unclear. 9 Others caution against the potential for 
overuse of the IVC filter.l° Controlled clinical trials to 
determine the role of IVC filters in DVT without 
pulmonary embolism or free-floating iliofemoral 
thrombus and without anticoagulation are lacking. 
We have recently noted the development of 
phlegmasia cerulea dolens in patients with DVT who 
were treated with percutaneous vena caval interrup- 
tion, without anticoagulation, as primary therapy for 
the DVT. To date only two isolated case reports 
address this potentially serious complication of vena 
caval interruption. We report he progression of four 
cases of DVT to phlegmasia fter percutaneous 
interruption of the IVC in lieu of anticoagulation. 
MATERIAL AND METHODS 
The study population consisted of all patients 
discharged from Stanford University Medical Center 
during a 12-month period, from August 1, 1993 to 
July 31, 1994, with a diagnosis of acute DVT, 
pulmonary embolism, or both. A computerized 
registry of all hospital discharges was organized by 
International Classification of Diseases Ninth Revi- 
sion and was searched for acute DVT and pulmonary 
embolism codes to generate a patient list of all 
patients with thromboembolic disease. This list was 
then searched for vena eaval interruption by catheter 
device or intravascular umbrella with use of Current 
Procedural Terminology coding of the procedures 
listed in the discharge summaries. 
All patient records with catheter-directed vena 
caval interruption were then retrospectively reviewed 
to validate the procedure and the diagnosis of DVT 
or pulmonary embolism in patients included in the 
study. The diagnosis of DVT was made with use of 
color-flow duplex ultrasound examination of the 
lower extremities, ascending venography, or both 
examinations. The diagnosis of pulmonary embolism 
was made by use of high probability ventilation- 
perfusion scanning or pulmonary angiography. 
These records were then reviewed for demo- 
graphic data including age, sex, indication for IVC 
filter, filter type, filter insertion site, concurrent 
medical conditions, risk factors for thromboembo- 
lism, and for use of anticoagulation. Patients were 
then categorized into two groups: group 1, IVC filter 
with anticoagulation, and group 2, IVC filter with- 
out anticoagulation. 
The records were then reviewed for the presence 
of thrombotic omplications developing after inser- 
tion of the vena cava filter. Phlegmasia cerulea dolens 
was defined as acute iliofemoral venous thrombosis 
associated with the sudden onset of severe leg pain, 
with swelling, edema, and cyanotic mottling. The 
presence of iliofemoral venous thrombosis was con- 
firmed by duplex ultrasonography and venography. 
Therapy for the phlegmasia was recorded. 
RESULTS 
From August 1993 through July 1994, 306 cases 
of DVT and 135 cases of pulmonary embolism were 
diagnosed at Stanford University Hospital. Of these 
patients, 47 had both pulmonary embolism and 
DVT, so that the total number of patients with 
thromboembolic disease for this year was 394. From 
this group of patients with venous thromboembolic 
disease, 33 percutaneous IVC filters were placed in 
32 patients for an incidence of vena caval filter 
insertion of 8%. The underlying disease in the 
patients receiving vena caval filters was pulmonary 
embolism in 15 (47%) and DVT in I7 (53%) 
patients. Diagnosis of pulmonary embolism was 
confirmed by pulmonary angiography in i3 patients 
(87%) and high probability ventilation-perfusion 
scanning in two patients (13%). Of patients with 
pulmonary embolism, l I patients had a coexistent 
DVT confirmed by duplex ultrasonography, and four 
patients were not evaluated for DVT. DVT was 
diagnosed by duplex ultrasonography in 17 patients 
without coexistent pulmonary embolism. In cases of 
DVT, the thrombus was limited to the popliteal or 
superficial femoral veins on initial evaluation in 
94.2%. 
Fourteen men and 18 women with a mean age of 
63.5 years (range 24 to 93) comprised the study 
population. Risk factors for venous thromboembo- 
lism were neoplasm in i5 patients (47%), trauma in 
three patients (9%), postoperative state in five 
patients (16%), and chronic illness with bed rest in 
nine patients (28%). 
Filter types included 30 titanium Greenfield filters 
(Medi-Tech, Inc., Watertown, Mass.), two Bird's 
Nest filters (Cook, Inc., Bloomington, Ind.), and one 
Venatech LGM filter (Vena-Tech, Evanston, Ill.) 
deployed in this series. The filter was deployed in the 
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internal jugular vein in 10 patients, in the common 
femoral vein in 22 patients, and via saphenous vein 
cutdown after operation in one patient. One patient 
had two Greenfield filters deployed sequentially 
through the same access site, the right common 
femoral vein, as a result of initial misplacement of the 
first filter. The initial filter deployed in this case was 
angulated and could not be adjusted, so the second 
filter was placed caudal to the first. 
Grouped by indication for vena caval interrup- 
tion, two patients (6%) had pulmonary embolism 
while receiving a full course of anticoagulant medi- 
cation; eight patients (25%) were admitted with 
pulmonary embolism, were given anticoagulants, 
and underwent prophylactic insertion of an IVC 
filter; five patients (16%) were admitted with pul- 
monary embolism and absolute contraindication to 
anticoagulation; two patients (6%) were admitted 
with DVT and absolute contraindication to anti- 
coagulation; five patients (16%) were admitted with 
DVT, were given anticoagulants, and underwent 
prophylactic insertion of an IVC filter; and 10 
patients (31%) were admitted with DVT and a 
relative contraindication to anticoagulation. A more 
informative grouping is the presence or absence of 
anticoagulation with the vena cava filter. In patients 
with pulmonary embolism, 10 patients received 
heparin anticoagulation with the IVC filter, and five 
patients did not. In patients with DVT, five patients 
received heparin anticoagulation with the IVC filter, 
and 10 patients did not. Therefore 15 patients 
received heparin anticoagulation with the IVC filter, 
and 17 patients with IVC filter were not given 
anticoagulants. 
• Phlegmasia cerulea dolens developed after place- 
ment of the vena caval filter in four of the 32 (12.5%) 
patients. No cases of phlegmasia cerulea dolens 
developed in the 15 patients with IVC filters receiv- 
ing heparin anticoagulation. Therefore the incidence 
of phlegmasia developing in patients with IVC filters 
and no heparin anticoagulation was 23.5% (four of 
17). In patients without documented pulmonary 
embolism or IVC filter and no heparin anticoagula- 
tion, the incidence of phlegmasia cerulea dolens was 
33% (four of 12). One of these four patients had 
development of bilateral phlegmasia related to IVC 
thrombosis after filter placement. 
The IVC filter was a titanium Greenfield type in 
all cases of phlegmasia cerulea dolens. The common 
femoral vein was the insertion sitc for the IVC filter 
in all cases of phlegmasia cerulea dolens. Phlegmasia 
cerulea dolens developed ipsilateral to the femoral 
vein insertion site in all cases. In two cases the 
insertion site was ipsilateral to the original DVT, and 
in two cases the insertion site was contralateral to the 
original DVT. 
Phlegmasia cerulea dolens developed a mean of 
4.5 days after insertion of the IVC filter (range 2 to 
10 days). All cases of phlegmasia cerulea dolens had 
iliofemoral venous thrombosis confirmed by duplex 
scanning and ascending venography. 
The stated reasons for not giving anticoagulants 
to the four patients with development of phlegmasia 
cerulea dolens were (1) development of DVT i4 days 
after craniotomy for ligation of an arteriovenous mal- 
formation in a 31-year-old man; (2) development of 
DVT in a 76-year-old man with prostatic ancer and 
remote history of lower gastrointestinal bleeding; (3) 
development of DVT 13 days after craniotomy and 
resection of a frontal meningioma in a 62-year-old 
woman; and (4) development ofDVT 11 days after 
craniotomy and resection of a parietal meningioma in 
a 65-year-old woman who had development of left 
hemiparesis after the resection. Patient 4 had two 
filters placed as described above. 
Patients 1 to 3 received heparin by continuous 
intravenous infusion, 100 units/kg load, and titration 
of an hourly infusion rate to maintain activated 
partial thromboplastin ime (aPTT) between 1.5 and 
2.5 times control after the diagnosis of phlegmasia 
was confirmed. The fourth patient was not given 
anticoagulant and had development of contralateral 
leg DVT and phlegmasia cerulea dolens within 48 
hours. This patient had persistent pain and swelling, 
yet no gangrene, and was treated with leg elevation 
and, subsequently, sequential compression devices. 
The three patients receiving heparin had resolution of 
their pain and swelling, and medication was success- 
fully changed to oral anticoagulants in two patients. 
Because of development of a heparin-associated 
antibody in the third patient, administration of 
heparin was discontinued, and oral anticoagulation 
with warfarin was begun. This 76-year-old man then 
had development of acute kidney failure, refused to 
undergo dialysis, and died 3 weeks after his admission 
to the hospital. 
DISCUSSION 
Venous thromboembolism represents a poten- 
tially fatal disease that, because of its often silent 
nature, its incidence, prevalence, and mortality rates 
are incompletely defined. The diagnosis of venous 
thromboembolism is largely limited to hospitalized 
patients, and most of our knowledge has been derived 
from this population. From a large community 
retrospective analysis, the average annual incidence of 
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DVT alone was 48 per 100,000, and the incidence of 
pulmonary embolism, with or without DVT was 23 
per 100,000, and the incidence increased exponen- 
tially with increasing age. n It is estimated that 
pulmonary embolism isthe primary cause of death in 
100,000 patients annually and a contributing cause 
of death in another 100,000 patients annually in the 
United States. 12 
Venous thromboembolic disease can be effec- 
tively managed by anticoagulation in most pa- 
tients. 2,a When anticoagulation cannot be used, or 
when it fails, there is an indication for mechanical 
interruption of the vena cava to provide a barrier 
to thromboembolism. Indications for interruption 
of the IVC are (1) recurrent pulmonary embolism 
while adequate anticoagulants are administered; (2) 
pulmonary embolism or DVT with a contraindi- 
cation to or complication from anticoagulation; (3) 
patients at high risk for pulmonary embolism de- 
spite adequate anticoagulation, such as a free- 
floating iliofemoral thrombus greater than 5 cm 
across; (4) in patients undergoing pulmonary 
embolectomy; (5) in patients undergoing elective 
operation with multiple risk factors for the devel- 
opment of thromboembolism or with prior history 
of venous thromboembolic disease, s 
Vena caval interruption has been predominantly 
managed by IVC filters since the initial introduction 
of these devices by their innovators 13Is and their 
clinical validation. 16-18 Subsequently, most of the 
published information on vena cava filters has been 
with the Greenfield filter, either stainless steel, or 
more recently titanium types. 19 Early experience with 
the Greenfield filter was notable for an IVC patency 
rate of 95%, with a recurrent pulmonary embolism 
rate of 5%. ~8 More recent experience with the tita- 
nium Greenfield filter showed no vena cava occlu- 
sions and prevention of recurrent pulmonary embo- 
lism in 97% of patients monitored over a more lim- 
ited time span than the earlier study. 7The mortality 
rate from filter complications alone has been low, 
0.16% in 1632 patients in 16 series reporting experi- 
ence with Greenfield vena caval filters, but filter com- 
plications have been common. 19,2° 
Thrombotic complications of vena cava filters 
have been infrequently reported, yet significant 
variations in reporting standards complicate this 
issue. 19 Several reports have documented a 20% to 
30% incidence of local femoral venous thrombosis at 
the insertion site of the vena cava filter. 21-23 Devel- 
opment ofphlegmasia cerulea dolens after placement 
of IVC filters has been less frequently reported in 
anecdotal case reports. 24,2s Worsening ofphlegmasia 
cerulea dolens after placement of an IVC filter has 
been more frequently observed. 26,27 Progression of 
DVT after placement of vena cava filters has been 
observed, often in patients who are believed to have 
a contraindication to anticoagulation yet ultimately 
require anticoagulation to control the thrombotic 
process. 27'2s Thus in most patients with DVT and 
indications for IVC filtration, concurrent anticoagu- 
lation is recommended, a position strongly advocated 
by Greenfield. z9 
The definition of true contraindications for anti- 
coagulation remains elusive. Clearly, patients with 
active ongoing hemorrhage and those with preexist- 
ing hemorrhagic disorders should not be given 
anticoagulants. Beyond these situations, no firm data 
exist contraindicating anticoagulation i  other situ- 
ations. Intuitively, recommendations against antico- 
agulation have been made in patients who have had 
"recent" surgery or trauma, yet the interval of time 
delimiting "recent" remains incompletely defined. 
Although the general risk of major bleeding from 
heparin anticoagulation approaches 5%, 30 there is no 
correlation between supratherapeutic aPTT levels 
while heparin therapy is used and bleeding. 31 In 
contrast here is evidence to support an increased 
incidence of recurrent venous thromboembolism 
with subtherapeutic aPTT levels while heparin 
therapy is used. 31 In a prospective study comparing 
intravenous heparin versus subcutaneous heparin 
therapies, there was a higher major hemorrhage rate 
in patients who had not had recent surgery than in 
those that had recent surgery. 32 It is from this study 
that the arbitrary 2-week postoperative time point 
arose, because the authors observed bleeding in 
patients less than 2 weeks after surgery, yet only two 
of 19 (10.5%) patients had major bleeding in this 
postoperative time period. The risk of major bleeding 
in the nonsurgical patients was 12.2% in the same 
study.  
In most circumstances, heparin anticoagulation is 
effective in preventing pulmonary embolism in pa- 
tients with venous thromboembolic disease. In pa- 
tients with DVT, anticoagulation reduces the risk of 
fatal pulmonary embolism to a rate between 0.14% 
and 0.30%. 8,a3 In patients with a documented 
pulmonary embolism, heparin anticoagulation re- 
duces the risk of recurrent fatal pulmonary embolism 
to a rate between 0.9% and 1.3%. 8,aa Furthermore, 
heparin anticoagulation retards the propagation of 
venous thrombosis in the calf and distal leg to the 
iliofemoral segments, diminishing the incidence of 
phlegmasia cerulea dolens. 
In this series, the contraindications to anticoagu- 
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lation were marginal, and in fact three of four patients 
who had development of phlegmasia while not 
receiving anticoagulants were subsequently given a 
full course of anticoagulant medication without 
bleeding complications. The one patient not given 
anticoagulants in this series most likely should have 
been. Furthermore, none of these four patients had 
their initial DVT extending into the iliofemoral 
venous segment. Perhaps in these patients with 
venous thromboembolic disease and a perceived risk 
for anticoagulation, one should return to operative 
venous thromboembolectomy before inserting a vena 
caval filter. Intraoperative pulmonary embolism is 
frequent during venous thrombectomies, yet fatal 
pulmonary embolism is rare. Long-term patency 
rates have been observed from 74% to 93%.  34 
Arteriovenous fistula creation can obviate the need 
for anticoagulation after venous thromboembo- 
lectomy. 
It is also interesting that all cases of phlegmasia 
cerulea dolens in this series developed ipsilateral to 
the common femoral venous insertion site. Others 
have reported an alarming incidence of local venous 
thrombosis at the insertion sites of vena cava filters, 
yet the incidence of concurrent anticoagulation i  
these series was not defined. 21-23 In a group of 
patients with documented venous thromboembolic 
disease who will not be given anticoagulants, the risk 
of extending the venous thrombotic process from an 
area of intimal injury must be magnified. Perhaps in 
this group of patients in need of vena caval interrup- 
tion yet who are not candidates for anticoagulation, 
consideration of a jugular insertion site for vena cava 
filters should be given. 
In all instances, the decision to place IVC filters in 
this series were made by the primary care team, 
without hematology or vascular surgery consulta- 
tions. With the newer low-profile delivery systems, 
most IVC filters will most likely be placed in 
angiography suites, often at the directive of primary 
care physicians. Because vascular surgeons are con- 
sulted for the complications of acute and chronic 
DVT, we believe strongly that consultation from a 
vascular surgeon is also indicated uring the analysis 
of treatment options for patients diagnosed with 
acute DVT. 
Short- and long-term follow-up of these filters 
will be essential to help further define the role ofvena 
caval filtration in patients with venous thromboem- 
bolic disease. As Greenfield 29 cautions, "It is obvious 
that this new device has made filter insertion remark- 
ably easy to accomplish. In the overall management 
of the patient with thrombotic disease, however, the 
filter has only a small role to play and it is incumbent 
on the physician who treats the patient o assume the 
responsibility for long term follow-up and care of the 
underlying disorder." From our experience, care of 
the underlying disorder should include anticoagula- 
tion if at all possible. 
IVC interruption can be lifesaving in select 
situations. Percutaneous deployment of IVC filters 
prevents most pulmonary embolism in patients with 
DVT. Yet methods of IVC interruption do not 
impact on the underlying process of venous throm- 
bosis and in fact may exacerbate the thrombotic 
process. Anticoagulation with intravenous heparin is 
safe and effective therapy for DVT in most patients, 
and true contraindications to anticoagulation remain 
incompletely defined. Anticoagulation should be 
maintained along with IVC filtration if at all possible. 
We believe percutaneous insertion ofvena cava filters 
should not replace anticoagulation i routine proxi- 
mal DVT and caution that relative contraindications 
to anticoagulation should be carefully scrutinized 
before recommending vena caval interruption as a 
primary therapy for DVT. If  a vena cava filter is 
required in a patient with DVT and who may not be 
given anticoagulant, consideration of a jugular vein 
insertion site is recommended. 
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